Skip to content
DataLookout
Menu

NCT04678401

IS-free Treg HaploHCT

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 9 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 17 words
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 2 of 9 entries
    • Site details revised
  2. Notable Enrollment target: 20 to 30v12 Show 6 more changesShow less
    • Primary completion date: Dec 31, 2029 to Aug 31, 2028
    • Eligibility criteria expanded, about 56 words
    • Study completion date: Dec 31, 2030 to Aug 31, 2029
    • Interventions: CD34+ Haplo Peripheral Blood Stem Cell (Procedure), Cyclophosphamide (Drug), Fludarabine (Drug), Mesna (Drug), Radiation (Radiation)… to CD34+ Haplo Peripheral Blood Stem Cell (Procedure), Cyclophosphamide (Drug), Fludarabine (Drug), Melphalan (Drug), Mesna (Drug), Radiation…
    • Study arms: 2 to 3
    • Study description shortened, about 3 words
  3. Notable Primary completion date: Dec 31, 2025 to Dec 31, 2029
    • Study completion date: Dec 31, 2027 to Dec 31, 2030
    v11
  4. Minor Primary completion date: Oct 31, 2025 to Dec 31, 2025
    • Study completion date: Oct 31, 2027 to Dec 31, 2027
    v10
  5. Notable Enrollment target: 10 to 20v7 Show 5 more changesShow less
    • Primary completion date: Dec 31, 2023 to Oct 31, 2025
    • Eligibility criteria expanded, about 28 words
    • Study completion date: Dec 31, 2024 to Oct 31, 2027
    • Study description revised
    • Study arms: 1 to 2
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Primary completion date: Dec 31, 2022 to Dec 31, 2023
    • Study completion date: Dec 31, 2023 to Dec 31, 2024
    v6
  2. Notable Primary completion date: Oct 31, 2021 to Dec 31, 2022
    • Study completion date: Oct 31, 2023 to Dec 31, 2023
    v4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2021 to Jan 12, 2021
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dose-limiting toxicities (DLT)
Timeframe: 30 days after hematopoietic cell transplantation (HCT)

Secondary (9)

Engraftment rate
secondary graft failure rate
graft vs host disease (GVHD) Rate
Mortality Rate-GVHD Relapse
Mortality Rate-GVHD Non- Relapse
Show 4 moreShow less
Survival Rate-Relapse-Free
Progression Free-Survival (PFS)
Survival Rate-Relapse-Free-GVHD
Overall survival rate

Arms and interventions

IS-FREE TREG GRAFT_ENGINEERED HaploHCT for relapsed/refractory AML or MDS EB-2 (Closed to Accrual)Experimental

Please note that this arm is closed due to meeting accrual goal as of June 2024. This arm (Cohort A) included patients with rel/ref AML/MDS, with active disease despite at least 1 prior line of therapy. Treatment plan and follow up schedule: Day -15 to -6: Myeloablative conditioning regimen Radiation: Total Myeloid and Lymphoid Irradiation (TMLI) on Days -15 to -11 OR Total Body Irradiation (TBI) on Days -13 to -11 Chemotherapy: Fludarabine on Days -10 to -6, Thiotepa on Days -10 to -9, and Cyclophosphamide and Mesna on Days -8 and -7 Day -4: Treg-enriched donor cell infusion and GVHD assessment Day -1: Unmodified donor T Cell infusion and GVHD assessment Day 0: CD34+ Haplo Peripheral Blood Stem Cell Transplant and GVHD assessment Days 30, 60, 100, 180, 365 post-HSCT, participants will undergo testing and assessment of minimal residual disease (MRD) and (GVHD).

IS-FREE TREG GRAFT_ENGINEERED HaploHCT for Ultra high-risk AML or MDS with mutated TP53Experimental

This arm (Cohort B) includes patients with ultra-high-risk AML/MDS that meets the definition of "Myeloid Neoplasms with mutated TP53" per the 2022 International Consensus Classification, regardless of remission status at the time of transplant. Treatment plan and follow up schedule: Day -15 to -6: Myeloablative conditioning regimen Radiation: Total Myeloid and Lymphoid Irradiation (TMLI) on Days -15 to -11 OR Total Body Irradiation (TBI) on Days -13 to -11 Chemotherapy: Fludarabine on Days -10 to -6, Thiotepa on Days -10 to -9, and Cyclophosphamide and Mesna on Days -8 and -7 Day -4: Treg-enriched donor cell infusion and GVHD assessment Day -1: Unmodified donor T Cell infusion and GVHD assessment Day 0: CD34+ Haplo Peripheral Blood Stem Cell Transplant and GVHD assessment Days 30, 60, 100, 180, 365 post-HSCT, participants will undergo testing and assessment of minimal residual disease (MRD) and (GVHD).

IS-FREE TREG GRAFT_ENGINEERED HaploHCT for Ultra high-risk AML or MDS with multi-hit or CK+ mut-TP53Experimental

This arm (Cohort C) includes patients with ultra-high-risk AML/MDS that meets definition of 'Myeloid Neoplasms with multi-hit or complex karyotype (CK+) mutated TP53' per 2022 International Consensus Classification, with response (AML with \<5% BM blasts/MDS with \<10% BM blasts). Treatment plan and follow up schedule: Day -11 to -5: Reduced intensity conditioning regimen Chemotherapy: Thiotepa on Day -11, Fludarabine on Days -10 to -7, and Melphalan on Day -6 Radiation: Total Body Irradiation (TBI) on Day -5 Day -4: Treg-enriched donor cell infusion and GVHD assessment Day -1: Unmodified donor T Cell infusion and GVHD assessment Day 0: CD34+ Haplo Peripheral Blood Stem Cell Transplant and GVHD assessment Days 30, 60, 100, 180, 365 post-HSCT, participants will undergo testing and assessment of minimal residual disease (MRD) and (GVHD).

Radiation: Radiation

Drugs: Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Melphalan

Biologicals: Treg-enriched donor cell, Unmodified donor T Cell

Procedures: CD34+ Haplo Peripheral Blood Stem Cell

Sites

1 site in 1 country

  • Dana Farber Cancer InstituteBoston, Massachusetts, United States